Key facts
- It has raised $115.0M across 1 recorded rounds; the latest was Later Stage VC (Series B) ($115.0M) in Sep 2020.
- Talaris Therapeutics has filed 1 Form D with the SEC, most recently Oct 2020 ($115.0M sold to 24 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Talaris Therapeutics
Create free account
No card required
Funding rounds
1 roundsSep 2020Later Stage VC (Series B)$115.0M▮
About Talaris Therapeutics
- Industry
- Biotechnology
PA Mark — not yet priced
Talaris Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Talaris Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Talaris Therapeutics in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.